Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 258818-34-7
2. 258818-34-7 (free Base)
3. At-2347
4. 2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic Acid
5. Glycylglycyl-l-valyl-l-leucyl-l-valyl-l-glutaminyl-l-prolylglycine
6. Larazotide [usan:inn]
7. Unii-zn3r5560zv
8. Larazotide-acetate
9. At 2347
10. Larazotide (usan/inn)
11. Zn3r5560zv
12. Chembl2105646
13. Dtxsid30180526
14. Chebi:177799
15. Zinc68009799
16. Db05645
17. H-gly-gly-val-leu-val-gln-pro-gly-oh
18. Hy-106268
19. Cs-0025478
20. D09351
21. 818l347
22. Q27295752
Molecular Weight | 725.8 g/mol |
---|---|
Molecular Formula | C32H55N9O10 |
XLogP3 | -3.6 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 21 |
Exact Mass | 725.40718899 g/mol |
Monoisotopic Mass | 725.40718899 g/mol |
Topological Polar Surface Area | 301 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1290 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in autoimmune diseases, diabetes mellitus type 1, and gastrointestinal diseases and disorders (miscellaneous).
AT-1001 is an orally administered octapeptide zonulin receptor antagonist that appears to exert its inhibitory effect on gliadin-induced tight junction disassembly by blocking putative zonulin receptors on the luminal surface of the small intestine.
ABOUT THIS PAGE
A Larazotide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Larazotide, including repackagers and relabelers. The FDA regulates Larazotide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Larazotide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Larazotide supplier is an individual or a company that provides Larazotide active pharmaceutical ingredient (API) or Larazotide finished formulations upon request. The Larazotide suppliers may include Larazotide API manufacturers, exporters, distributors and traders.
click here to find a list of Larazotide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Larazotide DMF (Drug Master File) is a document detailing the whole manufacturing process of Larazotide active pharmaceutical ingredient (API) in detail. Different forms of Larazotide DMFs exist exist since differing nations have different regulations, such as Larazotide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Larazotide DMF submitted to regulatory agencies in the US is known as a USDMF. Larazotide USDMF includes data on Larazotide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Larazotide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Larazotide suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Larazotide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Larazotide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Larazotide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Larazotide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Larazotide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Larazotide suppliers with NDC on PharmaCompass.
Larazotide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Larazotide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Larazotide GMP manufacturer or Larazotide GMP API supplier for your needs.
A Larazotide CoA (Certificate of Analysis) is a formal document that attests to Larazotide's compliance with Larazotide specifications and serves as a tool for batch-level quality control.
Larazotide CoA mostly includes findings from lab analyses of a specific batch. For each Larazotide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Larazotide may be tested according to a variety of international standards, such as European Pharmacopoeia (Larazotide EP), Larazotide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Larazotide USP).
LOOKING FOR A SUPPLIER?